Strength Seen in NovoCure (NVCR): Can Its 8% Jump Turn into More Strength?Zacks Investment Research • 06/23/22
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung CancerBusiness Wire • 06/21/22
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric CancerBusiness Wire • 06/03/22
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed GlioblastomaBusiness Wire • 05/26/22
NovoCure Limited's (NVCR) Management on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris SununuBusiness Wire • 04/19/22
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating FieldsBusiness Wire • 04/08/22
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 TrialBusiness Wire • 03/24/22